experimental treatment of ebola virus disease with brincidofovir.

Clicks: 255
ID: 137696
2016
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #32 of 234 articles by views in ensaio pesquisa em educação em ciências

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 234 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND:The nucleotide analogue brincidofovir was developed to prevent and treat infections caused by double-stranded DNA viruses. Based on in vitro data suggesting an antiviral effect against Ebola virus, brincidofovir was included in the World Health Organisation list of agents that should be prioritised for clinical evaluation in patients with Ebola virus disease (EVD) during the West African epidemic. METHODS AND FINDINGS:In this single-arm phase 2 trial conducted in Liberia, patients with laboratory-confirmed EVD (two months of age or older, enrolment bodyweight ≥50 kg) received oral brincidofovir 200 mg as a loading dose on day 0, followed by 100 mg brincidofovir on days 3, 7, 10, and 14. Bodyweight-adjusted dosing was used for patients weighing <50 kg at enrolment. The primary outcome was survival at Day 14 after the first dose of brincidofovir. Four patients were enrolled between 01 January 2015 and 31 January 2015. The trial was stopped following the decision by the manufacturer to terminate their program of development of brincidofovir for EVD. No Serious Adverse Reactions or Suspected Unexpected Serious Adverse Reactions were identified. All enrolled subjects died of an illness consistent with EVD. CONCLUSIONS:Due to the small sample size it was not possible to determine the efficacy of brincidofovir for the treatment of EVD. The premature termination of the trial highlights the need to establish better practices for preclinical in-vitro and animal screening of therapeutics for potentially emerging epidemic infectious diseases prior to their use in patients. TRIAL REGISTRATION:Pan African Clinical Trials Registry PACTR201411000939962.
Reference Key
dunning2016plosexperimental Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Jake Dunning;Stephen B Kennedy;Annick Antierens;John Whitehead;Iza Ciglenecki;Gail Carson;Rupa Kanapathipillai;Lyndsey Castle;Rebecca Howell-Jones;Raul Pardinaz-Solis;Jennifer Grove;Janet Scott;Trudie Lang;Piero Olliaro;Peter W Horby;RAPIDE-BCV trial team
Journal ensaio pesquisa em educação em ciências
Year 2016
DOI
10.1371/journal.pone.0162199
URL
https://doi.org/10.1371/journal.pone.0162199
Keywords
medicinescience

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.